Drug may reduce chronic pain for spinal cord injuries

October 31, 2013 by Emil Venere
Purdue researcher Riyi Shi is leading work to study the role of a known neurotoxin in  chronic pain for people who suffer from paralysis. A drug that has been shown to remove the toxin might be used to treat the pain. Credit: Purdue University photo/Michel Schweinsberg

(Medical Xpress)—Researchers have discovered that a known neurotoxin may cause chronic pain in people who suffer from paralysis, and a drug that has been shown to remove the toxin might be used to treat the pain.

The toxin, called acrolein, is produced in the body after nerve cells are injured, triggering a cascade of biochemical events thought to worsen the injury's severity. The drug , which has been approved by the U.S. Food and Drug Administration for hypertension, has been shown to be effective in reducing acrolein levels in the body.

New research shows hydralazine is effective in reducing chronic pain in laboratory animals and potentially in people who have suffered neurotrauma resulting in paralysis, said Riyi Shi (pronounced Ree Shee), a professor of neuroscience and in Purdue's Department of Basic Medical Sciences, School of Veterinary Medicine, and Weldon School of Biomedical Engineering.

"Beyond paralysis, drastically impairs the quality of life for spinal cord injury victims. " he said. "Pain can persist for decades post-injury, which could contribute to depression and suicide."

The research is a collaboration between Purdue and the Indiana University School of Medicine. New findings are detailed in a research paper appearing this month in the Journal of Neurochemistry.

Researchers studied the role acrolein plays in hypersensitivity to pain in laboratory rats and the effectiveness of hydralazine in reducing the pain.

"It turns out that acrolein is a very important compound behind ," Shi said. "In a chronic pain situation, a stimulus that ordinarily might feel pleasant, even just a little touch, could cause pain."

Findings show the quantity of acrolein increases after a spinal cord injury and may activate - protein channels called TRPA1 - contained in pain-sensory nerve fibers of dorsal root ganglia located alongside the spine. Following spinal cord injury, the dorsal root ganglia could be affected biochemically or directly through physical trauma.

"The amplification of pain can be exacerbated in spinal cord injury due to acrolein's direct activation of pain receptors, as well as acrolein-induced inflammation that further intensifies pain sensation," Shi said. "Sometimes you have pain even without stimulation. You can have excruciating pain just sitting there."

Findings also indicate that injury causes a three-fold increase in the number of TRPA1 channels, which could further amplify pain caused by acrolein. The research showed hydralazine significantly reduces pain in experiments that measure a rat's reaction to stimulation.

"Even if we delay administration of hydralazine we can still reduce the pain, meaning not only acute but might be reduced by acrolein-scavenging treatment," Shi said. "This could be promising news for millions of spinal cord injury victims who may suffer from debilitating ."

Explore further: Testing method promising for spinal cord injuries, multiple sclerosis

More information: Acrolein involvement in sensory and behavioral hypersensitivity following spinal cord injury in the rat, Michael R. Due,  Jonghyuck Park, Lingxing Zheng, Michael Walls, Yohance M. Allette, Fletcher A. White, and Riyi Shi, Journal of Neurochemistry, 2013.

ABSTRACT
Growing evidence suggests that oxidative stress, as associated with spinal cord injury (SCI), may play a critical role in both neuroinflammation and neuropathic pain conditions. The production of the endogenous aldehyde acrolein, following lipid peroxidation during the inflammatory response, may contribute to peripheral sensitization and hyperreflexia following SCI via the TRPA1-dependent mechanism.  Here we report that there are enhanced levels of acrolein and increased neuronal sensitivity to the aldehyde for at least 14 days after SCI. Concurrent with injury-induced increases in acrolein concentration, is an increased expression of TRPA1 in the lumbar (L3-L6) sensory ganglia. As proof of the potential pronociceptive role for acrolein, intrathecal injections of acrolein revealed enhanced sensitivity to both tactile and thermal stimuli for up to 10 days, supporting the compound's pro-nociceptive functionality. Treatment of SCI animals with the acrolein scavenger, hydralazine, produced moderate improvement in tactile responses as well as robust changes in thermal sensitivity for up to 49 days. Taken together, these data suggests that acrolein directly modulates SCI-associated pain behavior, making it a novel vietherapeutic target for preclinical and clinical SCI as an analgesic.

Related Stories

Testing method promising for spinal cord injuries, multiple sclerosis

June 13, 2013
(Medical Xpress)—A medical test previously developed to measure a toxin found in tobacco smokers has been adapted to measure the same toxin in people suffering from spinal cord injuries and multiple sclerosis, offering ...

Researchers use lithium to ease pain caused by anti-cancer drug

October 30, 2013
(Medical Xpress)—Taxol, generically called paclitaxel, is a widely used drug in chemotherapy treatments. Taxol is used to treat cancer in the lungs, ovaries and breast, but it can also cause severe neuropathic pain and ...

Women's chronic pain is more complex, more severe

October 24, 2013
(Medical Xpress)—New research from the University of Adelaide has found that chronic pain in women is more complex and harder to treat than chronic pain in men.

Researchers find possible breakthrough to relieve pain following spinal cord injury

November 30, 2011
A collaborative research group – led by researchers at Cleveland Clinic – published findings that indicate a one-time injection immediately after spinal cord injury can limit pain for an extended period of time.

New treatment of pain in diabetics: Spinal cord stimulation appears effective

August 29, 2013
There are about a million people in the Netherlands with diabetes. Approximately 15% of these patients suffer from chronic pain. This is burning or stinging pain caused by abnormal function of nerve endings, most likely partially ...

Recommended for you

Female mouse embryos actively remove male reproductive systems

August 17, 2017
A protein called COUP-TFII determines whether a mouse embryo develops a male reproductive tract, according to researchers at the National Institutes of Health and their colleagues at Baylor College of Medicine, Houston. The ...

Two-step process leads to cell immortalization and cancer

August 17, 2017
A mutation that helps make cells immortal is critical to the development of a tumor, but new research at the University of California, Berkeley suggests that becoming immortal is a more complicated process than originally ...

New Pathology Atlas maps genes in cancer to accelerate progress in personalized medicine

August 17, 2017
A new Pathology Atlas is launched today with an analysis of all human genes in all major cancers showing the consequence of their corresponding protein levels for overall patient survival. The difference in expression patterns ...

New technique overcomes genetic cause of infertility

August 17, 2017
Scientists have created healthy offspring from genetically infertile male mice, offering a potential new approach to tackling a common genetic cause of human infertility.

Are stem cells the link between bacteria and cancer?

August 17, 2017
Gastric carcinoma is one of the most common causes of cancer-related deaths, primarily because most patients present at an advanced stage of the disease. The main cause of this cancer is the bacterium Helicobacter pylori, ...

Inhibiting a protein found to reduce progression of Alzheimer's and ALS in mice

August 17, 2017
(Medical Xpress)—A team of researchers with Genetech Inc. and universities in Hamburg and San Francisco has found that inhibiting the creation of a protein leads to a reduction in the progression of Alzheimer's disease ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.